Positive topline results were announced from a phase 3 study of obinutuzumab in patients with lupus nephritis.

William Blair analyst Matt Phipps in a note to investors wrote that despite the patient deaths, the totality of the data ...

Lupus nephritis progression may be faster in patients with interstitial fibrosis/tubular atrophy (IFTA). Now a nomogram may predict it.

Kezar Life Sciences saw its share tumble more than 42% to 40.77 yesterday, after it revealed it was voluntarily pausing ...

According to the safety findings, four Grade Five serious adverse events were reported during the Phase II PALIZADE trial.

"Adicet Bio begins enrolling subjects in Phase I trial of autoimmune disease therapy" was originally created and published by ...

Kezar Life Sciences said it voluntarily suspended enrollment and dosing in a clinical trial of a treatment for an autoimmune kidney disease after four patients died.

The San Francisco-based company said it had informed the U.S. Food and Drug Administration and European regulators of the decision to pause enrollment and dosing in the trial. An independent study ...

Kezar Life Sciences went all in on its autoimmune candidate zetomipzomib after a restructuring last year. | The voluntary ...

Artificial Intelligence (AI) has gained a critical role in clinical practice and biomedical research. The use of Machine ...

Three different versions of Alexandria Wingate appear in a trio of purple paintings the Baltimorean started while a fine art ...

South San Francisco-based Kezar Life Sciences Inc. voluntarily stopped its phase IIb Palizade trial of zetomipzomib in active lupus nephritis, following four fatal, or grade 5, serious adverse events ...